243 related articles for article (PubMed ID: 27746185)
1. Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins.
Appeltshauser L; Weishaupt A; Sommer C; Doppler K
Exp Neurol; 2017 Jan; 287(Pt 1):84-90. PubMed ID: 27746185
[TBL] [Abstract][Full Text] [Related]
2. Anti-CNTN1 IgG3 induces acute conduction block and motor deficits in a passive transfer rat model.
Doppler K; Schuster Y; Appeltshauser L; Biko L; Villmann C; Weishaupt A; Werner C; Sommer C
J Neuroinflammation; 2019 Apr; 16(1):73. PubMed ID: 30953561
[TBL] [Abstract][Full Text] [Related]
3. Contactin-1 and Neurofascin-155/-186 Are Not Targets of Auto-Antibodies in Multifocal Motor Neuropathy.
Doppler K; Appeltshauser L; Krämer HH; Ng JK; Meinl E; Villmann C; Brophy P; Dib-Hajj SD; Waxman SG; Weishaupt A; Sommer C
PLoS One; 2015; 10(7):e0134274. PubMed ID: 26218529
[TBL] [Abstract][Full Text] [Related]
4. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Manso C; Querol L; Mekaouche M; Illa I; Devaux JJ
Brain; 2016 Jun; 139(Pt 6):1700-12. PubMed ID: 27017186
[TBL] [Abstract][Full Text] [Related]
5. Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy.
Appeltshauser L; Brunder AM; Heinius A; Körtvélyessy P; Wandinger KP; Junker R; Villmann C; Sommer C; Leypoldt F; Doppler K
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32736337
[TBL] [Abstract][Full Text] [Related]
6. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.
Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34845096
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.
Cortese A; Lombardi R; Briani C; Callegari I; Benedetti L; Manganelli F; Luigetti M; Ferrari S; Clerici AM; Marfia GA; Rigamonti A; Carpo M; Fazio R; Corbo M; Mazzeo A; Giannini F; Cosentino G; Zardini E; Currò R; Gastaldi M; Vegezzi E; Alfonsi E; Berardinelli A; Kouton L; Manso C; Giannotta C; Doneddu P; Dacci P; Piccolo L; Ruiz M; Salvalaggio A; De Michelis C; Spina E; Topa A; Bisogni G; Romano A; Mariotto S; Mataluni G; Cerri F; Stancanelli C; Sabatelli M; Schenone A; Marchioni E; Lauria G; Nobile-Orazio E; Devaux J; Franciotta D
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31753915
[TBL] [Abstract][Full Text] [Related]
8. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies.
Doppler K; Appeltshauser L; Wilhelmi K; Villmann C; Dib-Hajj SD; Waxman SG; Mäurer M; Weishaupt A; Sommer C
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):720-8. PubMed ID: 25694474
[TBL] [Abstract][Full Text] [Related]
9. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN.
Piepers S; Jansen MD; Cats EA; van Sorge NM; van den Berg LH; van der Pol WL
J Neuroimmunol; 2010 Dec; 229(1-2):256-62. PubMed ID: 20920831
[TBL] [Abstract][Full Text] [Related]
10. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy.
Doppler K; Appeltshauser L; Villmann C; Martin C; Peles E; Krämer HH; Haarmann A; Buttmann M; Sommer C
Brain; 2016 Oct; 139(Pt 10):2617-2630. PubMed ID: 27474220
[TBL] [Abstract][Full Text] [Related]
11. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy.
Yuki N; Watanabe H; Nakajima T; Späth PJ
J Neurol Neurosurg Psychiatry; 2011 Jan; 82(1):87-91. PubMed ID: 20667861
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
Pascual-Goñi E; Fehmi J; Lleixà C; Martín-Aguilar L; Devaux J; Höftberger R; Delmont E; Doppler K; Sommer C; Radunovic A; Carvajal A; Smyth S; Williams L; Mazanec R; Potočková V; Hinds N; Cassereau J; Viala K; Lefilliatre M; Nicolas G; Foley P; Leypoldt F; Keddie S; Lunn MP; Zimprich F; Nunkoo VS; Löscher WN; Martínez-Martínez L; Díaz-Manera J; Rojas-Garcia R; Illa I; Rinaldi S; Querol L
Brain; 2021 May; 144(4):1183-1196. PubMed ID: 33880507
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies.
Sudo M; Miyaji K; Späth PJ; Morita-Matsumoto K; Yamaguchi Y; Yuki N
Int Immunopharmacol; 2016 Nov; 40():11-15. PubMed ID: 27567246
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.
Dalakas MC
Neurotherapeutics; 2022 Apr; 19(3):741-752. PubMed ID: 35290608
[TBL] [Abstract][Full Text] [Related]
15. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.
Berger M; McCallus DE; Lin CS
J Peripher Nerv Syst; 2013 Dec; 18(4):275-96. PubMed ID: 24200120
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.
Rieben R; Roos A; Muizert Y; Tinguely C; Gerritsen AF; Daha MR
Blood; 1999 Feb; 93(3):942-51. PubMed ID: 9920844
[TBL] [Abstract][Full Text] [Related]
17. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia.
Miura Y; Devaux JJ; Fukami Y; Manso C; Belghazi M; Wong AH; Yuki N;
Brain; 2015 Jun; 138(Pt 6):1484-91. PubMed ID: 25808373
[TBL] [Abstract][Full Text] [Related]
18. [Immunoglobulins and physiopathology: actual indications].
Mouthon L; Guilpain P
Rev Med Interne; 2007 May; 28 Spec No. 1():11-7. PubMed ID: 17768833
[TBL] [Abstract][Full Text] [Related]
19. Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition.
Sudo M; Yamaguchi Y; Späth PJ; Matsumoto-Morita K; Ong BK; Shahrizaila N; Yuki N
PLoS One; 2014; 9(9):e107772. PubMed ID: 25259950
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1.
Peng W
Immunol Lett; 2012 Apr; 143(2):146-51. PubMed ID: 22289946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
